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Abstract Three mitogen activated protein kinase-activated
protein kinase 2 (MAPKAP kinase 2, MK2) interacting pro-
teins were identi¢ed using a yeast two-hybrid approach. ShcA, a
signaling phospho-protein, human polyhomeotic 2 (HPH2), a
transcriptional regulator, and highly similar to smoothelin
(HSTS), which is related to the cytoskeletal associated protein
smoothelin, interact speci¢cally with MK2. The interaction of
MK2 with the 66 kDa isoform of ShcA, p66ShcA, and HPH2
was con¢rmed using co-immunoprecipitation. MK2 is activated
with p66ShcA co-expression and p66ShcA is an in vitro substrate
for MK2, further demonstrating their association and suggest-
ing a biological role for p66Shc in MK2 activation.
( 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Mitogen activated protein kinase-activated protein kinase 2
(MAPKAP kinase 2 or MK2) is a serine threonine kinase
directly phosphorylated and activated by the p38 mitogen
activated protein kinase (MAPK)/reactivating kinase [1], the
mammalian orthologue of Hog1 which is required for adap-
tive responses to osmotic stress in Saccharomyces cerevisiae
[2]. P38 MAPKs are activated by cellular stress including os-
motic and heat shock, anisomycin, H2O2, and UV light as
well as by several pro-in£ammatory cytokines including tumor
necrosis factor-K (TNF-K) and interleukin-1 (IL1) and by bac-
terial lipopolysaccharide (LPS). The p38 MAPKs, in turn,
regulate a number of environmental stress responses including
actin micro¢lament dynamics, levels of intracellular reactive
oxygen species (ROS), apoptosis, and the biosynthesis of sev-
eral proin£ammatory cytokines including TNF-K, IL1, and
IL6 [3^5].
MK2 is likely to mediate several p38 regulated pathways
since it is a direct substrate for p38. In addition, cells isolated
from mice deleted for MK2 are de¢cient in the LPS induced
biosynthesis of several pro-in£ammatory cytokines regulated
by p38 including TNF-K, IL6, and IL1 [6^12]. A pleiotropic
function for MK2 is revealed through both MK23/3 cells
which show defects in migration [11,12] and MK2^/^ mice
which show neuroprotection against ischemic injury [8] as
well as increased susceptibility to infection by Listeria mono-
cytogenes [9] and to in£ammatory bowel disease [10]. These
phenotypes are likely to result from the misregulation of dis-
tinct pathways otherwise requiring appropriate regulation by
a number of MK2 binding proteins and substrates.
Several approaches have identi¢ed potential physiological
substrates and binding proteins for MK2 including adapter
and cytoskeletal associated proteins [13,14], transcriptional
and translation regulators [15^18], regulatory enzymes [19^
21], and RNA binding proteins [22,23]. We chose a two-hy-
brid approach toward identifying MK2 binding proteins and
potential substrates to better understand the pleiotropic func-
tion of MK2. We identi¢ed: ShcA, a signaling phospho-pro-
tein [24], human polyhomeotic 2 (HPH2), a transcriptional
regulator [25], and highly similar to smoothelin (HSTS) which
is related to the cytoskeletal associated protein smoothelin
[26,27], as MK2 binding proteins. Both HPH2 and the long
isoform of ShcA, p66ShcA, interact with MK2 in mammalian
cells and p66ShcA is a substrate for MK2 in vitro suggesting a
biological role for these proteins in MK2 regulated pathways.
2. Materials and methods
2.1. Plasmid construction
MK2, MK2K93R, MK2vN (amino acids 41^400), MK2vC (amino
acids 1^370), MK2Cat (catalytic domain amino acids 48^338), and
COT/TPL2 were ampli¢ed with N: ggatccccgaattccat and C: ctcgagc-
ggccgc terminal linkers and cloned into pGBKT7 (Clontech) NdeI-
XhoI. HPH2 (amino acids 656^858) was cloned using S¢I and XhoI,
into pCMV-HA (Clontech). V5-p66ShcA in pCMV-PSORT was pur-
chased from Invitrogen.
2.2. Yeast two-hybrid system
The yeast two-hybrid screen was executed using a human bone
marrow MATCHMAKER cDNA library cloned into pACT2 (Clon-
tech) and pre-transformed into yeast strain Y187. PGBKT7-
MK2K93R, transformed into yeast strain AH109, was used in a mat-
ing strategy according to the MATCHMAKER Library user manual
(Clontech). MK2 interacting proteins were tested against pGBKT7,
pGBKT7-53, pGBKT7-Lamin (Clontech), and pGBKT7-COT/TPL2
by negative selection. Positive colonies were selected by growth and
color on SD -Ade/-His/-Leu/-Trp and SD -Leu/-Trp/X-K-Gal respec-
tively. One sequence each of ShcA, HPH2, and HSTS was identi¢ed
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as selectively interacting with MK2K93R. MK2 interaction domains
were mapped using pGBKT7-MK2, pGBKT7-MK2vN, pGBKT7-
MK2vC, and pGBKT7-MK2Cat.
2.3. Cell culture, antibodies and transfection
The human embryonic kidney HEK-293T and HeLa (ATCC) cell
lines were cultured in Dulbecco’s modi¢ed Eagle’s medium supple-
mented with 10% (v/v) fetal calf serum (FCS) at 37‡C in humidi¢ed
air with 5% CO2. RAW 264.7 cells (ATCC) were cultured in RPMI
1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/l
sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES, and 1.0 mM
sodium pyruvate, 90%; fetal bovine serum, 10%. Tagged proteins
were detected using anti-HA polyclonal (1:200), anti-Myc monoclonal
(1:500) (Clontech), anti-Myc polyclonal (1:200) (Santa Cruz Biotech-
nology), and anti-V5 monoclonal (1: 5000) (Invitrogen) antibodies.
Cellular proteins were detected with anti-actin monoclonal (1:5000)
(United States Biological), and anti-phospho-Hsp27 S86 (1:1000)
(Cell Signaling Technologies) antibodies.
HEK-293T cells were transfected using a calcium phosphate trans-
fection system (Gibco BRL Life Technologies). HeLa and RAW 264.7
cells were transfected using Lipofectamine-2000 (Invitrogen). HeLa
cells were starved in 0.5% (v/v) FCS overnight prior to stimulation
with anisomycin (Sigma Aldrich) 2 Wg/ml, for 30 min. RAW 264.7
cells were stimulated with LPS (Salmonella typhosa, Sigma Aldrich)
50 ng/ml, for 6 h.
2.4. Immunoprecipitation and immunoblots
Cells were lysed in Triton lysis bu¡er (TLB): 20 mM Tris pH 7.5,
125 mM NaCl, 1% (v/v) Triton X-100, 100 mM NaF, 25 mM sodium
L-glycerophosphate, 10 mM sodium vanadate with Complete Protease
inhibitor cocktail (Roche Molecular Biochemicals) and after centrifu-
gation, lysate protein concentration was measured (DC Protein Assay,
Bio-Rad). Following addition of NuPage LDS sample bu¡er (Invitro-
gen) supplemented with 20 mM dithiothreitol (DTT), samples were
boiled, centrifuged, resolved by sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE, 5^12% acrylamide), and
transferred to nitrocellulose (0.45 Wm) membranes (Invitrogen). Mem-
branes were processed as in [11]. Incubations with primary phospho-
speci¢c antibodies were overnight at 4‡C in 5% bovine serum albumin
(Sigma-Aldrich) in phosphate bu¡ered saline^0.1% Tween 20. Bound
proteins were detected with an ECL detection kit (Amersham Bio-
sciences) and quantitated using the Molecular Imager FX densitome-
ter (Bio-Rad) with Quant One software. For immunoprecipitations,
lysates were pre-cleared with protein G Sepharose (Amersham Bio-
sciences) and incubated for 2^6 h with primary antibodies in TLB
prior to addition of protein G Sepharose for an additional 2 h at
4‡C. After centrifugation the Sepharose matrix was washed twice in
TLB and diluted in NuPage LDS sample bu¡er supplemented with
20 mM DTT.
2.5. Kinase assays
Immunoprecipitates from V5-p66ShcA transfected HEK-293T cells
were washed in TLB, RIPA bu¡er (50 mM Tris^HCl pH 7.4, 150
mM NaCl, 1% (v/v) Triton X-100, 0.1% SDS), and in kinase bu¡er
(0.5 M Tris pH 7.5, 0.2 M MgCl2). 5 Wl of the Sepharose matrix
was used as substrate for kinase reactions with recombinant MK2
(50 nM), 1 WM ATP, 0.5 WCi [Q-33P]ATP, 3 mM DTT in 1Ukinase
bu¡er for 30 min at room temperature. Reactions were terminated by
addition of NuPage LDS sample bu¡er supplemented with 20 mM
DTT and resolved by SDS^PAGE. Phosphorylated substrate was de-
tected using the Molecular Imager FX (Bio-Rad).
2.6. Analysis for secreted TNF-K
Medium from transfected RAW 264.7 cells was assayed for secreted
TNF-K using enzyme linked immunosorbent assays (ELISA) (Quan-
tikine M mouse TNF-K immunoassay kit, RpD Systems).
3. Results
3.1. MK2 interacting proteins identi¢ed using two-hybrid
Full length catalytically inactive MK2 (MK2K93R) [11]
was used in executing the two-hybrid screen because inactive
kinases have been reported to bind interacting proteins more
stably thereby allowing for stronger transcriptional activation
of two-hybrid reporter genes [28]. We identi¢ed ShcA, an
adapter signaling phospho-protein, HPH2, a transcriptional
regulator, and HSTS, which is highly related to the cytoskel-
etal associated protein smoothelin, as binding proteins for
MK2 (Fig. 1).
We tested ShcA, HPH2, and HSTS for their interaction
with empty vector expressing the GAL4 activation domain
alone and three unrelated proteins: p53, lamin, and COT/
TPL2. Since there was no detectable interaction between these
proteins their interaction with MK2 is speci¢c. Additionally,
Fig. 1. MK2 interacting proteins identi¢ed using two-hybrid. A^D: ShcA, HPH2, and HSTS interact with MK2 in yeast cells. Horizontal lines
indicate MK2 interaction domains identi¢ed from the screen. A: Amino acid designations in ShcA correspond to the longest isoform: p66ShcA,
66 kDa, 52 kDa, and 46 kDa. Domain delineations are (A) CH1 and 2: collagen homology domains 1 and 2, PTB: phospho-tyrosine binding
domain, and SH2: Src homology domain; (B) N-A and N-B: conserved N-terminal domains, Hd-1: homology domain I, Zn: zinc coordination
domain, SAM: sterile K motif; (C) ABD: actinin type actin binding domain. A: Serine phosphorylation sites in ShcA: S36 and S138, predicted
MK2 and CaM-KII consensus site: S17. D: Comparison of HSTS, unnamed protein product Mus musculus (Mus), and smoothelinLc2
(smoLc2) using ClustalW. Black and gray shading indicate identical and similar amino acids respectively. Sequences were identi¢ed with
BLAST database searches and downloaded from GenBank (accession numbers are gi21751336 for HSTS, gi12844213 for unnamed protein Mus
musculus, and gi8119288 for smoLc2). SmoSc2 start codon at aa 457 (solid arrow), C-terminal homology with HSTS begins at aa 545 (dashed
arrow), actinin type actin binding domain (dotted line).
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all three MK2 binding proteins bound MK2 and MK2K93R
equally, therefore their binding is not an artifact of the kinase
inactive mutant MK2K93R. Using several MK2 deletion mu-
tants, we found that the catalytic domain of MK2 (aa 48^338)
is su⁄cient to confer the interaction with all three proteins
(data not shown).
3.2. MK2 co-immunoprecipitates with p66ShcA and HPH2 in
mammalian cells
The interaction of ShcA and HPH2 with MK2 in mamma-
lian cells was con¢rmed using co-immunoprecipitation. We
used a construct encoding the longer ShcA isoform, p66ShcA,
in this and in subsequent experiments to analyze the interac-
tion between MK2 and ShcA since p66ShcA is regulated by
serine phosphorylation and like the p38 pathway, mediates
cellular responses to stress [24,29]. Myc-tagged MK2
(Myc-MK2) was co-expressed with either V5-tagged p66ShcA
(V5-p66ShcA), HA-tagged HPH2 (HA-HPH2), or HA-tagged
p38 (HA-p38) as a positive control in 293T cells. Immunopre-
cipitation of cell lysates with anti-V5 or anti-HA antibodies
and subsequent immunoblotting using an anti-Myc antibody
to detect MK2 showed that all three proteins co-immunopre-
cipitate with MK2 (Fig. 2A,B). Quantitative immunoblot
analyses show increased MK2 levels with p66ShcA, HPH2, or
p38 co-expression indicating that MK2 stability increases with
binding. P38 levels increase with MK2 co-expression suggest-
ing that p38 stability also increases when co-expressed with
MK2. The interaction of MK2 with p66ShcA, HPH2, and p38
appears to be constitutive since activation of MK2 with ani-
somycin ([18,30] ; unpublished results), does not a¡ect the for-
mation of these complexes as assayed by co-immunoprecipi-
tation (Fig. 2).
Fig. 2. MK2 co-immunoprecipitates with p66ShcA, HPH2, and p38 expressed in 293T cells. A,B: V5-p66ShcA, HA-HPH2, HA-p38, and Myc-
MK2 were expressed in 293T cells. Cell lysate protein levels were quantitated and equal amounts of protein were analyzed. Co-immunoprecipi-
tation using anti-V5 or anti-HA antibodies followed by immunoblotting with an anti-Myc antibody shows that MK2 co-immunoprecipitates
(A) with p66ShcA and (B) with HPH2, and p38. Immunoprecipitation (IP), Western blot (WB).
Fig. 3. MK2 is activated with p66ShcA co-expression in HeLa cells. A: V5-p66ShcA and Myc-MK2 were expressed in HeLa cells. Cell lysate pro-
tein levels were quantitated and equal amounts of protein were analyzed using immunoblotting. Phospho-Hsp27 increases with anisomycin
treatment and with MK2 expression in unstimulated cells. A further increase in phospho-Hsp27 is observed with co-expression of MK2 and
p66ShcA. B,C: Phospho-Hsp27 normalized to basal phospho-Hsp27 levels in unstimulated vector control transfected cells (B) and normalized
with Myc-MK2 expression levels (C).
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3.3. MK2 is activated when co-expressed with p66ShcA in HeLa
cells
Phosphorylation of endogenous Hsp27, a physiological sub-
strate for MK2 [6,31], is responsive to MK2 activity in HeLa
cells (unpublished results) and therefore was used to assay
for MK2 activity when co-expressed with p66ShcA. HeLa cells
were transfected with vector alone, V5-p66ShcA, or Myc-MK2
as controls or were co-transfected with both V5-p66ShcA and
Myc-MK2. Subsequent immunoblotting for phosphorylated
Hsp27 (phospho-Hsp27) shows an increase in phospho-
Hsp27 with anisomycin, a stimulus which is known to activate
the p38/MK2 pathway in this cell type ([17] ; unpublished
results). In unstimulated cells an increase in basal phospho-
Hsp27 levels is apparent with expression of exogenous MK2,
which is not observed in p66ShcA or vector control expressing
cells (Fig. 3A). Densitometry shows the increase in basal
phospho-Hsp27 seen with MK2 expression to be two-fold
over empty vector or p66ShcA expressing cells. Basal phos-
pho-Hsp27 levels are further increased when MK2 is co-ex-
pressed with p66ShcA. Densitometry shows this increase to be
three-fold over levels detected when MK2 is expressed alone
(Fig. 3B). As shown in 293T cells, MK2 levels increase with
co-expression of p66ShcA further demonstrating their interac-
tion. The observed increase in basal phospho-Hsp27 is there-
fore likely to re£ect increased MK2 activity as well as in-
creased levels of MK2 protein. The basal phospho-Hsp27
level in cells co-expressing MK2 and p66ShcA is 2.3-fold over
the phospho-Hsp27 level in control transfected cells when
normalized with MK2 protein expression (Fig. 3C) and is
likely the result of increased MK2 activation with p66ShcA
co-expression.
3.4. MK2 is activated when co-expressed with p66ShcA in RAW
264.7 cells
To further con¢rm that MK2 is activated with p66ShcA bind-
ing, we assayed for secreted TNF-K from RAW 264.7 cells co-
expressing MK2 and p66ShcA. RAW 264.7 cells are of macro-
phage origin and express the cell surface receptor CD14 there-
by conferring their responsiveness to LPS measured here by
TNF-K release. TNF-K regulation through MK2 is known to
require MK2 enzymatic activity [11], therefore increased TNF-
K levels with MK2 and p66ShcA co-expression should re£ect
MK2 activation. RAW 264.7 cells were transfected with vector
alone, V5-p66ShcA, or Myc-MK2 alone as controls or were co-
transfected with both V5-p66ShcA and Myc-MK2. TNF-K
ELISAs showed that TNF-K secretion increases eight-fold
with LPS stimulation and that expression of MK2 or
p66ShcA alone does not potentiate TNF-K biosynthesis. In con-
trast, when MK2 and p66ShcA are co-expressed, TNF-K bio-
synthesis increases 1.5-fold after stimulation (Fig. 4A).
Quantitative Western blot analysis shows that both Myc-
MK2 and V5-p66ShcA are expressed in RAW 264.7 cells
although in contrast to in 293T and in HeLa cells, both
Myc-MK2 and V5-p66ShcA levels are lower in co-transfected
versus control transfected cells. This does not re£ect an over-
all decrease in protein levels because equal amounts of protein
were loaded in each lane as shown using an actin speci¢c
antibody (Fig. 4B). The increase in TNF-K biosynthesis there-
fore should re£ect an increase in MK2 activity and not in
MK2 expression since MK2 protein levels when co-expressed
with p66ShcA are below that observed in cells expressing MK2
alone.
3.5. MK2 phosphorylates p66ShcA in vitro
Serine 36 phosphorylation is required for p66ShcA function
in mediating cellular responses to oxidative stress [24]. A pre-
dicted recognition sequence for both MK2 and calcium/cal-
modulin dependent protein kinase-II (CaM-KII) is located at
serine 17: RXXS, although the preferred recognition site for
MK2 includes a hydrophobic amino acid at N-5: hydropho-
bic aa-Xaa-Arg-Xaa-Xaa-Ser [32]. To determine if p66ShcA is a
substrate for MK2, V5-p66ShcA was expressed in 293T cells.
After expression, p66ShcA was immunoprecipitated using an
anti-V5 antibody and used as substrate with activated re-
combinant MK2 in an in vitro kinase assay. When compared
with vector control transfected cells, immunoprecipitates from
p66ShcA transfected cells show robust phosphorylation at
66 kDa demonstrating that p66ShcA is a substrate for MK2
in vitro (Fig. 5).
4. Discussion
A two-hybrid approach using an oligo-dT primed library
generated from human bone marrow identi¢ed ShcA, HPH2,
and HSTS as MK2 speci¢c interacting proteins (Fig. 1). The
interaction of MK2 with the longest isoform of ShcA,
p66ShcA, and HPH2 amino acids 656^858 was con¢rmed using
co-immunoprecipitation. MK2 protein levels increase with co-
expression of p66ShcA, HPH2, or p38 in 293T or in HeLa cells,
most likely due to increased MK2 stability with binding (Figs.
2 and 3), further demonstrating their interaction. P38 levels
also increase with co-expression of MK2 (Fig. 2B) supporting
a previously reported role for MK2 in stabilizing p38 levels
through binding [11].
Fig. 4. MK2 is activated with p66ShcA co-expression in RAW 264.7
cells. A: ELISA analysis shows an increase in TNF-K secretion
when MK2 and p66ShcA are co-expressed. B: V5-p66ShcA and Myc-
MK2 were expressed in RAW 264.7 cells. Cell lysate protein levels
were quantitated and equal amounts of protein were analyzed as
shown with an anti-actin speci¢c antibody.
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HPH2 belongs to the polycomb group of proteins, which
maintain appropriate regulation of the homeotic loci through
the formation of chromatin associated complexes. Mutations
at these loci result in anterior^posterior transformations [33],
defects in neural crest and heart development, and severe hy-
poplasia in the thymus and spleen suggesting that these pro-
teins regulate hematopoiesis [34,35]. The hematopoietic cell
type speci¢c defect in mice deleted for MK2 is illustrated by
a dramatic decrease in the production of a number of pro-
in£ammatory cytokines, largely due to a misregulation in pro-
cessing or translation of their mRNAs [6,7]. As yet, a defect in
hematopoietic cell development has not been revealed in mice
deleted for MK2, therefore a biological role for MK2 in bind-
ing HPH2 has yet to be elucidated and may also include a role
in modulating HPH2’s regulation of the homeotic loci.
The HSTS gene predicted amino acid sequence shows high-
est identity, 82%, with unnamed protein product Mus muscu-
lus but extends 31 amino acids N-terminal to the murine pro-
tein’s start codon, indicating that this murine sequence is
incomplete or is a truncated isoform of HSTS (Fig. 1D).
The amino acid sequence of HSTS reported in GenBank is
also likely incomplete since it does not begin with a methio-
nine start codon (Fig. 1D). HSTS and unnamed protein prod-
uct Mus musculus are related to the smoothelin family of cy-
toskeletal associated proteins. Small and large (L) smoothelin
isoforms (Fig. 1D) are generated through distinct transcrip-
tion initiation sites with additional isoforms, c1^c3, generated
through C-terminal alternative splicing [26,27]. HSTS is most
similar to smoothelinLc2 sharing highest identity, 97%, from
aa 545 through the conserved actinin type actin binding do-
main with the exception of a 76 aa deletion in this region (Fig.
1D). N-terminal to aa 545 the homology between HSTS and
smoothelinLc2 lessens signi¢cantly representing previously
unreported divergence within the smoothelinL family. Of
note, smoothelinLc2 is speci¢cally expressed in vascularized
tissues such as smooth muscle and heart where MK2 is also
highly expressed [36]. The function of the smoothelin proteins
is unknown, however, their association with actin suggests
that HSTS may localize MK2 to the cytoskeleton to regulate
micro¢lament dynamics possibly by phosphorylating its sub-
strate Hsp27. This possibility is further supported by the cel-
lular migration defect shown by cells deleted for MK2, a
phenotype attributed to reduced phosphorylation of an F-ac-
tin cross-linking protein [12] or misregulation of actin poly-
merization [11] in the absence of MK2.
The ShcA locus encodes three Shc isoforms p46ShcA,
p52ShcA, and p66ShcA. P46ShcA and p52ShcA activate the Ras
MAPK pathway through cell surface receptors while p66ShcA
is proposed to down-regulate signaling through its competitive
binding with p46ShcA and p52ShcA [37,38]. Unlike the smaller
isoforms of ShcA, p66ShcA also regulates oxidative stress re-
sponses and is regulated by serine phosphorylation [24,29].
MK2 interacts with the ShcA C-terminus shared by all three
ShcA isoforms, therefore MK2 should interact with both
p46ShcA and p52ShcA in mammalian cell based assays.
Although MK2 has not been associated with signaling directly
through cell surface receptors, binding or phosphorylation by
MK2 could regulate p46ShcA and p52ShcA through a yet to be
described mechanism.
The HeLa and RAW 264.7 cell assays provide a biological
context in which to evaluate MK2 activity through two MK2
regulated responses, Hsp27 phosphorylation and TNF-K re-
lease [6]. Co-expression with p66ShcA activates MK2 as shown
by increased HeLa cell phospho-Hsp27, which is apparent
even when normalized with MK2 levels (Fig. 3). Since MK2
levels increase with p66ShcA co-expression, the observed in-
crease in MK2 activity is likely to result from both increased
protein stability and kinase activity. P66ShcA over-expression
itself may also indirectly activate MK2 by increasing basal
levels of intracellular ROS [29,39] which then stimulate the
p38 stress activated protein kinase cascade [4].
MK2 activation with p66ShcA co-expression, as assayed by
increased TNF-K secretion from RAW 264.7 cells, further
illustrates the interaction between these proteins, and is re-
vealed only after stimulation. MK2 localization studies have
shown that when activated, MK2 translocates from the nu-
cleus to the cytoplasm [30,40,41]. Therefore, in RAW 264.7
cells, activated MK2 may become tethered in the cytoplasm
through its interaction with cytosolic p66ShcA where it can
better access cytoplasmic substrates which regulate the biosyn-
thesis of TNF-K mRNAs [23]. The observed increase in TNF-
K secretion may also result directly from increased MK2 acti-
vation with p66ShcA binding as observed in HeLa cells. The
reduced expression of both MK2 and p66ShcA in RAW 264.7
cells when co-transfected may result from lowered transfection
e⁄ciency or degradation upon co-expression in this cell type.
Our ¢nding that p66ShcA is a direct in vitro substrate for
MK2 suggests that MK2 regulates p66ShcA activity (Fig. 5).
Studies including site directed mutagenesis are under way to
identify which p66ShcA amino acid is phosphorylated by MK2.
Resistance to stress induced cellular apoptosis and an ex-
tended lifespan, both attributed to lowered levels of intracel-
lular ROS, characterize animals deleted for p66ShcA [24]. To
date, an extended lifespan has not been reported for animals
deleted for MK2. However, MK23/3 mice do have enlarged
germinal centers which are attributed to decreased apoptosis
in the cells that comprise these tissues [6]. This phenotype may
be due to misregulation of p66ShcA in the absence of MK2.
Reduced phospho-Akt levels, also resulting from lowered lev-
els of intracellular ROS, have been reported for p66ShcA=
Mefs [38]. Although phosphorylation of Akt by MK2 has
been reported in vitro [21], MK2 regulation of Akt in cells,
has yet to be determined.
In summary, using yeast two-hybrid and subsequent co-im-
munoprecipitation we have identi¢ed three MK2 interacting
proteins: ShcA, HPH2 and HSTS. The interaction of MK2
with p66ShcA activates MK2 as shown by the increased phos-
phorylation of its physiological substrate Hsp27, and an in-
Fig. 5. MK2 phosphorylates p66ShcA in vitro. 293T cells were trans-
fected with V5-p66ShcA to generate substrate or with empty vector
as a control. Coomassie staining (middle panel) and immunoblotting
using an anti-V5 antibody (lower panel) show that p66ShcA is ex-
pressed. The anti-V5 antibody immunoprecipitates an endogenous
protein from 293T cells that is a weak substrate for MK2. Robust
phosphorylation at 66 kDa is only observed with immunoprecipi-
tates from cells expressing V5-p66ShcA.
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creased level of LPS induced TNF-K production, an MK2
mediated response [6]. The phosphorylation of p66ShcA by
MK2 further supports a biological role for the interaction
of MK2 with p66ShcA in cells. Future experiments are needed
to further understand the precise mechanism underlying these
interactions and to determine a physiological role for MK2
interacting proteins in MK2 regulated pathways.
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